MLLT3 通过抑制 HMGB1 核进入和 MAGEA1 M5C 修改来调节黑色素瘤茎和进展
Yaling Li1,2,3, Hong Liu4, Jingyi Li1,3
1Institute of Biomedical and Health Engineering, Shen Zhen Institutes of Advanced Technology, Chinese Academy of Science, Shenzhen, Guangdong, 518055, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|December 24, 2024
概括
转录因子MLLT3抑制了黑色素瘤干细胞的特性和进展. 淘汰MLLT3会激活路径,促进干细胞转化和黑色素瘤的发展,突出显示MLLT3作为治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症干细胞研究研究
背景情况:
- 黑色素瘤干细胞驱动瘤的发生,发展和转移.
- 识别黑色素瘤干的关键调节者对于有效的治疗至关重要.
研究的目的:
- 阐明转录因子MLLT3在调节黑色素瘤干和进展中的作用.
- 研究MLLT3在黑色素瘤中的功能背后的分子机制.
主要方法:
- 研究了MLLT3与HMGB1,YBX1和MAGEA1.1的相互作用.
- 分析了MLLT3对P53.3的直接转录调节.
- 研究了MLLT3和特定的微RNA (miR-542-3p/miR-3922-3p) 之间的相互作用.
- 使用单细胞RNA测序 (scRNA-seq) 在MLLT3绝杀性黑色素瘤细胞上.
主要成果:
- MLLT3抑制HMGB1的核入口和YBX1介导的MAGEA1m5C读数,降低了MAGEA1mRNA的稳定性.
- MLLT3直接转录P53,抑制黑色素瘤茎,扩散和转移.
- 在黑色素瘤细胞中MLLT3淘汰改变了细胞子集,激活了TP53和MAPK通路,并诱导了干细胞转化.
结论:
- 转录因子MLLT3在黑色素瘤中起到抑制基因的作用.
- MLLT3通过抑制关键瘤性通路来调节黑色素瘤的干和进展.
- 在黑色素瘤治疗中,MLLT3是一个有前途的治疗点.
相关概念视频
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Mesenchymal Stem Cells
4.6K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.6K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Induced Pluripotent Stem Cells
3.9K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
3.9K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Cancer Stem Cells and Tumor Maintenance
4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K


